BPC-157

Effects measured: Treated rats showed better tendon-to-bone healing functionally (higher Achilles functional index), biomechanically (higher load to failure, stiffness and Young's modulus), and histologically (better collagen organization, more vascularization, more type I collagen). BPC-157 also counteracted the worsening of healing caused by the corticosteroid methylprednisolone.

Side effects: No adverse events reported in this study

Sources: Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-9.

Effects measured: All three delivery routes produced consistent improvements in ligament healing across functional, biomechanical, macroscopic and histological measures versus controls. The abstract reports the direction of effect (improved healing) but does not give per-measure numeric values.

Side effects: No adverse events reported in this study

Sources: Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-61.

Effects measured: Treated rats showed improved macroscopic and microscopic findings, greater biomechanical strength, and better functional recovery. The junction defect reportedly disappeared completely by day 42, muscle atrophy was counteracted, inflammatory infiltrate was reduced, and markers eNOS and COX-2 were normalized with reduced oxidative stress versus untreated controls.

Side effects: No adverse events reported in this study

Sources: Japjec M, Horvat Pavlov K, Petrovic A, et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. Biomedicines. 2021;9(11):1547.

Effects measured: BPC-157 reduced ulcer area, with ulcer-formation inhibition ratios of 45.7% to 65.6%. The 800 ng/kg intramuscular dose gave inhibition of 65.5%, 65.6% and 59.9% across the three models. It accelerated rebuilding of glandular epithelium and granulation tissue. Intramuscular dosing was more effective than intragastric and worked at a lower effective dose; effect compared favorably with famotidine controls.

Side effects: No adverse events reported in this study

Sources: Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-6.

Effects measured: Treated rats showed faster axonal regeneration: improved motor action potentials, higher sciatic functional index scores, and no autotomy behavior versus controls. Histomorphometry showed larger myelinated fiber diameter, greater myelin thickness, and higher fiber density.

Side effects: No adverse events reported in this study

Sources: Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1-3):33-41.

Effects measured: BPC-157 was well tolerated and caused no serious toxicity in any of the four species. Single-dose studies showed no test-related effects. In dogs, a reversible decrease in creatinine occurred at 2 mg/kg (not at lower doses), reversing after a 2-week withdrawal. No genotoxicity and no embryo-fetal toxicity were observed. No LD50 was reported in the abstract.

Side effects: Local tolerance testing showed only mild irritation. The only notable systemic finding was a reversible decrease in serum creatinine in dogs at 2 mg/kg. No serious toxicity, no genotoxicity, and no embryo-fetal toxicity were observed.

Sources: Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665.